NUWE NUWELLIS INC

Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Live video webcast on Thursday, August 21st at 2:40 PM ET

MINNEAPOLIS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company delivering fluid management solutions for critically ill patients, today announced that it will present at the being held virtually August 19-21, 2025.

Details for the presentation are as follows:

Date/Time: Thursday, August 21, 2025 at 2:40 PM ET

Presenter: Registration Link:

About Webull Financial

Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit .

About Nuwellis

Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit or visit us on LinkedIn or X, formerly known as Twitter.

For further information, please contact:

Investor Contact:

JTC Team, LLC

Jenene Thomas

(908) 824-0775

Media Contact:

Leah McMullen

Director of Communications



EN
15/08/2025

Underlying

NUWENUWELLIS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NUWELLIS INC

 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of ...

Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company’s board with complementary expertise in public company leadership, capital markets, and medical device commercialization. “These appointments reflect our c...

February 26, 2026 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial R...

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026 MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of th...

February 24, 2026 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Appoints Carisa Schultz as Chief Financial Officer

Nuwellis Appoints Carisa Schultz as Chief Financial Officer Schultz brings public company healthcare finance and medical technology experience to support Nuwellis’ next phase of growth MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at ...

January 30, 2026 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Announces $5 Million Private Placement and Warrant Inducement...

Nuwellis Announces $5 Million Private Placement and Warrant Inducement Transaction, Priced At-The-Market MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced that it has entered into a securities purchase agreement with an institutional and accredited investor (the “Investor”) for the purchase and sale of 994,537 shares (the “Shares”) of the Company’s common stock, $0.0001 par value (the “Common Stock”) or (pre-funde...

January 29, 2026 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Enters into Definitive Agreement to Acquire Rendiatech, Advan...

Nuwellis Enters into Definitive Agreement to Acquire Rendiatech, Advancing Its Cardiorenal Portfolio Strategy Transaction positions Nuwellis to expand into real-time kidney function monitoring and strengthen its long-term cardiorenal platform, subject to customary closing conditions MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced that it has entered into a Securities Purchase Agreement to acquire all of the issued and outstanding capital s...

January 29, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch